CD8A and neoplasm: IDO inhibitors (e.g., epacadostat) reduce tumor growth and promote the proliferation of CD8+ T cells and NK cells in human peripheral blood mononuclear cells (PBMCs) ex vivo and are currently under clinical trial (Table 2) [148].